Research & Development
Patients & Caregivers
Investors & News
Regulation Kits
Careers
home | contact | site map   search

ARGENT Regulated Transcription (including Three-Hybrid Technology)

Papers that describe the use of three-hybrid technology are grouped in a separate list at the end of this section.

2006


2005


2004


2003


2002


2001


2000

  • Clackson, T. (2000) Regulated gene expression systems. Gene Ther 7:120-5.
    Reviews the various systems being developed for regulating gene expression in the context of gene therapy.
  • Pollock, R., Issner, R., Zoller, K., Natesan, S., Rivera, V.M., and Clackson, T. (2000) Delivery of a stringent dimerizer-regulated gene expression system in a single retroviral vector. Proc Natl Acad Sci USA 97:13221-6.
    Describes several improvements in the rapamycin regulated transcription system, including incorporation of more potent transcriptional activation domains to improve the level of target gene transcription and the incorporation of the entire system into a single retroviral vector. A variety of cell lines transduced with the all-in-one retroviral vector display negligible basal expression and give induction ratios of at least three orders of magnitude in the presence of rapamycin or a nonimmunosuppressive analog.

1999


1998


1997


1996


Three-Hybrid techology

A particular use of dimerizer-controlled transcription is in three-hybrid assays and screens. In these applications the "third hybrid" is the dimerizer, and gene activation serves merely as an assay to report on the interaction between a dimerizer and the two fusion proteins, rather than as the end in itself. Three-hybrid can be used to identify target proteins for a given small molecule, or vice versa. Most of the three-hybrid papers below use the transcriptional system although a few use alternative readouts.


2006


2005


2004


2003


2002


2000


1996

  • Licitra, E.J., and Liu, J.O. (1996) A three-hybrid system for detecting small ligand-protein receptor interactions. Proc Natl Acad Sci USA 93:12817-21.
    Describes the use of the chemical dimerizer concept to develop a "three-hybrid" system for identifying or characterizing novel small molecule-protein interactions. In this proof-of-concept, a heterodimerizer comprising FK506 and dexamethasone is used to bring together transcription factor fragments fused to a glucocorticoid receptor and FKBP, activating reporter gene expression in yeast. By substituting dexamethasone (or FK506) for a novel ligand, and the glucocorticoid receptor for a cDNA library, this system could be used to discover receptors for novel ligands; or conversely to screen for new ligands to known receptors.
Email Page  Print Page
©2008 ARIAD Pharmaceuticals, Inc.
Terms and Conditions   Privacy Policy   Safe Harbor   Map & Directions